Braveheart Bio (BRVE) OrbiMed Advisors (10% Owner) Buys $34.92M Stock

What Happened

• OrbiMed Advisors LLC (reported as a 10% owner via affiliated funds) recorded conversions of preferred securities into Braveheart Bio common stock and purchased additional shares in the company's IPO. The filing shows 9,132,420 shares acquired via conversion and two open-market/private purchases of 1,666,667 and 273,333 shares at $18.00 each (total purchase = $34,920,000). The report also lists a reported disposition of 40,000,000 shares via conversion at $0 (see footnotes for ownership structure).

Key Details

• Transaction date: August 7, 2026; Form 4 filed August 11, 2026 (appears timely).
• Purchases: 1,666,667 shares @ $18.00 = $30,000,006; 273,333 shares @ $18.00 = $4,919,994; total purchased = $34,920,000.
• Conversions: 9,132,420 shares acquired via conversion of Series A preferred into common (no cash paid); 40,000,000 shares reported as disposed via conversion at $0.
• Shares owned after transaction: not specified in the excerpt provided.
• Footnotes of note:
  • F1: Series A Preferred automatically converted into common on a one-for-4.38 basis upon the IPO closing (no payment).
  • F2: The purchased shares reflect participation in the IPO.
  • F3–F5: Securities are held by OrbiMed-affiliated funds (OrbiMed Private Investments IX, LP and OrbiMed Genesis Master Fund, L.P.); OrbiMed Advisors is the managing member and disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing is joint and notes OrbiMed designated an employee (Erez Chimovits) to the issuer’s board.

Context

• This filing reflects institutional activity by a 10% holder (OrbiMed and affiliated funds), not an executive insider—such purchases typically reflect institutional participation in an IPO rather than individual insider sentiment.
• The conversion entries are simple corporate events: Series A preferred converted into common stock at IPO (no cash). The reported $34.92M in purchases are cash buys at the IPO price of $18.00/share.